8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
1/41
Obesity,CardiacHealth, and
Bupropion/Naltrexone THE DREAM AND THEN !HTMARE
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
2/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
3/41
Obesity
▪
One"third o# the $% population is obese▪ One"third o# the $% population is o&er'ei(ht▪ Associated 'ith a plethora o# )edical co)plications
▪ T*DM▪ C+D▪ HTN▪ Depression▪ CAD▪ %tro e▪ %o)e cancers
American Journal of Preventive Medicine
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
4/41
Obesity
▪
Obesity"related )orbidity leads to increasedhospitali-ation and (reater )ortality▪ %econd to s)o in( as the leadin( cause o# pre&entable
death▪ Esti)ated )edical costs o# obesity . 011 billion per
annu)▪ 2e' dru(s a&ailable due to e3cacy and sa#ety concerns
▪ 2en"phen
▪ 45i#estyle )odi6cation has lon( been considered a)ainstay o# therapy #or obesity, but his inter&ention has
produced only )odest 'ei(ht loss and no reduction in)a7or ad&erse cardio&ascular e&ents 8MACE9:; 8 JAM
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
5/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
6/41
Obesity
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
7/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
8/41
T'o Dru(s
▪
Bupropion 8B$
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
9/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
10/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
11/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
12/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
13/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
14/41
Conclusion
▪
B$< @ NA5 co)bination treat)ent 'or ed in syner(y toreduce #ood inta e▪ E=ect li ely due to increased
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
15/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
16/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
17/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
18/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
19/41
Conclusions
▪
B$< @ NA5 coad)inistration leads to a 'ei(ht"reducin(anorectic e=ect▪ 5on(er ter) studies needed to sho' di&er(ence
bet'een B$< @ NA5 and B$< @ <▪
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
20/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
21/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
22/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
23/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
24/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
25/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
26/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
27/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
28/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
29/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
30/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
31/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
32/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
33/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
34/41
Conclusions
▪ t is not possible to assess nonin#eriority due to earlytrial ter)ination
▪ 4Cardio&ascular sa#ety o# this treat)ent re)ainsuncertain and 'ill re uire e&aluation in a ne'ade uately po'ered outco)e trial:;
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
35/41
My conclusion
▪
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
36/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
37/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
38/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
39/41
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
40/41
Clic icon to add picture
8/15/2019 Obesity, Cardiac Health, And Bupropion-Naltrexone
41/41